AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 SEP 12 - (NewsRx.com & NewsRx.net) -- by Sonia Bell-Nichols, senior medical writer - Upregulated expression of an extracellular enzyme seems be responsible for the invasiveness of breast cancers. Diminishing its activity at the molecular level could be one way of curbing breast cancer metastasis, researchers suggest.
In earlier studies, Dawn A. Kirschmann and colleagues at the Holden Comprehensive Cancer Center at The University of Iowa in Iowa City found that lysyl oxidase (LOX) expression, responsible for degrading the "glue" that holds cells together, is higher in breast cancers that are invasive than in breast cancers that are not.
A subsequent study has examined LOX at a molecular level in breast cancer and has determined that LOX and its analogs can be contained at both a genetic level and an enzymatic level in metastatic breast cancer cell lines.
Kirschmann's evaluation detected high levels of mRNA expression by LOX and LOX-like (LOXL) enzymes "only in breast cancer cell lines with highly invasive phenotypes."
"LOX and LOXL2 showed the strongest association with invasive potential in both highly invasive/metastatic breast cancer cell lines tested (MDA-MB-231 and Hs578T)," the team said.
Transfection of the two cell lines with antisense oligonucleotides to LOX limited their ability to disseminate into collagen/gelatin matrices. The enzymatic inhibitor beta-aminopropionitrile also incapacitated breast cancer cell invasiveness by ...